Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · IEX Real-Time Price · USD
35.96
+0.63 (1.78%)
At close: Apr 26, 2024, 4:00 PM
36.05
+0.09 (0.25%)
After-hours: Apr 26, 2024, 5:49 PM EDT
Revolution Medicines Employees
Revolution Medicines had 378 employees on December 31, 2023. The number of employees increased by 132 or 53.66% compared to the previous year.
Employees
378
Change (1Y)
132
Growth (1Y)
53.66%
Revenue / Employee
$30,635
Profits / Employee
-$1,154,410
Market Cap
5.92B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 378 | 132 | 53.66% |
Dec 31, 2022 | 246 | 58 | 30.85% |
Dec 31, 2021 | 188 | 63 | 50.40% |
Dec 31, 2020 | 125 | 30 | 31.58% |
Dec 31, 2019 | 95 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
R1 RCM | 30,000 |
Grifols | 23,737 |
DENTSPLY SIRONA | 15,000 |
Bausch + Lomb | 13,300 |
Elanco Animal Health | 9,800 |
Option Care Health | 7,802 |
Ionis Pharmaceuticals | 927 |
Apellis Pharmaceuticals | 702 |
RVMD News
- 17 days ago - Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins - GlobeNewsWire
- 19 days ago - Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins - GlobeNewsWire
- 22 days ago - Revolution Medicines to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 - GlobeNewsWire
- 2 months ago - Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 2 months ago - Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 - GlobeNewsWire
- 4 months ago - Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 months ago - Revolution Medicines Completes Acquisition of EQRx - GlobeNewsWire